Neurexan Prescription Is Associated with Lower Risk of Sleep Disorder Recurrence and Depression Prevalence as Compared to Z-Drugs and Benzodiazepines: A Retrospective Database Analysis in Germany
Open Access
- 16 July 2024
- journal article
- research article
- Published by MDPI AG in Healthcare
- Vol. 12 (14) , 1413
Abstract
Real-world evidence on the association between natural medicinal products and the recurrence of sleep disorders is currently limited, particularly when compared to the evidence reported for prescription hypnotics. In a retrospective cohort analysis, we investigated patients with sleep disorders prescribed either the natural medicinal product Neurexan (Nx4), benzodiazepines, or nonbenzodiazepines (Z-drugs) using the IQVIA Disease Analyzer database, which encompasses electronic medical records nationwide in Germany. A 1:1 matching procedure based on age, sex, prevalent depression, anxiety or adjustment disorder, and the number of medical consultations in the past 12 months resulted in four cohorts: patients prescribed Nx4 were matched with those prescribed Z-drugs (two cohorts with 8594 matched patients each), and another cohort of patients prescribed Nx4 were matched with those prescribed benzodiazepines (7779 matched pairs). Results from multivariable-adjusted Cox regression models demonstrated that Nx4 was associated with a significantly lower risk of recurrent sleep disorder diagnosis within 30–365 days after prescription compared to both Z-drugs (HR = 0.65, 95%CI = 0.60–0.70, p < 0.001) and benzodiazepines (HR = 0.85, 95%CI = 0.79–0.93, p < 0.001). Additionally, Nx4 was associated with a lower prevalence of depression compared to Z-drugs (HR = 0.90, 95%CI = 0.83–0.98, p = 0.020) and benzodiazepines (HR = 0.89, 95%CI = 0.82–0.97, p = 0.009). These findings suggest an association between Nx4 and improved sleep and mental health outcomes. However, due to inherent limitations in the study design, the causality of this relationship cannot be stated.Keywords
Funding Information
- Heel GmbH, Germany
This publication has 72 references indexed in Scilit:
- The Comparative Effectiveness and Safety of Insomnia Drugs: A Systematic Review and Network Meta-Analysis of 153 Randomized TrialsDrugs, 2023
- Comparative efficacy of hypnotics in young and middle-aged adults with insomnia: a systematic review and network meta-analysisSleep and Breathing, 2023
- Association between insomnia and the incidence of myocardial infarction: A systematic review and meta‐analysisClinical Cardiology, 2023
- Associations between insomnia symptoms and prescription opioid and benzodiazepine misuse in a nationally representative sampleAddictive Behaviors, 2022
- The FORTA (Fit fOR The Aged) List 2021: Fourth Version of a Validated Clinical Aid for Improved Pharmacotherapy in Older AdultsDrugs & Aging, 2022
- Schlafstörungen – Prävalenz, Bedeutung und Implikationen für die Prävention und Gesundheitsförderung2021
- ‘Z’‐hypnotics versus benzodiazepines for the treatment of insomniaProgress in Neurology and Psychiatry, 2018
- S3-Leitlinie Nicht erholsamer Schlaf/SchlafstörungenSomnologie, 2017
- The Associations of Insomnia With Costly Workplace Accidents and ErrorsArchives of General Psychiatry, 2012
- Epidemiology of severe insomnia and its consequences in GermanyEuropean Archives of Psychiatry and Clinical Neuroscience, 2001